Drilldown: Medicines

None (2) · Linagliptin (1) · Nifedipine (1) · Sitagliptin (1)

Ajovy (1) · Emgality (1) · Januvia; with metformin Janumet/Janumet XR (1) · Procardia, Procardia XL, Adalat CC, Afeditab CR (1) · Tradjenta; with metformin Jentadueto (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antianginals|Antianginal]] (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) · [[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Calcium_channel_blockers|Calcium channel blocker (dihydropyridine)]] (1) · [[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) · [[:Category:Incretin_modulators|Incretin pathway modulator]] (2) · [[:Category:Tocolytics|Tocolytic (off-label)]] (1)

None (2) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"', '"`UNIQ--vote-00000749-QINU`"', '"`UNIQ--vote-0000074A-QINU`"', '"`UNIQ--vote-0000074B-QINU`"', '"`UNIQ--vote-0000074C-QINU`"' (1) · '"`UNIQ--vote-00000764-QINU`"' (1) · '"`UNIQ--vote-0000117B-QINU`"' (1)

100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) · ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

10, 20 mg IR capsules; 30, 60, 90 mg ER tablets (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · 5 mg tablets; combination with metformin (1)

100 mg/d (1) · 120 mg/d (ER); IR not for chronic hypertension (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 5 mg/d (1) · 675 mg/quarter (1)

MI reports) (1) · Oral (2) · Oral; sublingual IR is discouraged (uncontrolled BP drops (1) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 hours (2) · IR 4-8 hours; ER 24 hours (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

2-5 hours (IR); ER formulations extend functional duration via osmotic/matrix release'"`UNIQ--ref-0000074D-QINU`"' (1) · ~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) · ~27 days (1) · ~31 days (1)

Not formally established (1) · Not formally established (high SC) (1) · ~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)

Limited data; avoid (2) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Oral nifedipine is one of the preferred agents for severe hypertension in pregnancy and for tocolysis in preterm labor.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (3)